Aurora Cannabis is urging shareholders to reject Curaleaf’s hostile bid while highlighting approximately $149 million in cash. Aurora says the proposal would give Curaleaf control of cash belonging to shareholders and replace ownership of a debt-free Business with Curaleaf shares, exposing investors to the bidder’s Debt and other stated risks.
Key Highlights
- Curaleaf carries more than $1 billion in debt, Aurora says.
- Aurora’s special committee and board received a written financial-adviser opinion dated September 1.
- Aurora says Curaleaf would gain control of remaining Shareholder funds upon closing.
Aurora Cannabis Inc. (NASDAQ: ACB) is urging shareholders to reject Curaleaf’s hostile bid, saying the offer undervalues the business and puts future upside at risk. Aurora says it had approximately $149 million in cash as of June 30, 2026, and that shareholders would receive only part of that value if the transaction closes.
Aurora Challenges Curaleaf’s Offer
Aurora says the proposal values its business at a significant discount to other cannabis companies and provides no meaningful change-of-control premium. The company also argues that Curaleaf’s premium calculation presents a more favorable picture than the value shareholders would actually receive.
Cash Ownership and Shareholder Exposure
Aurora says it is debt-free, while Curaleaf has more than $1 billion in debt. Under the hostile bid, Curaleaf would gain control of Aurora’s remaining shareholder cash after closing, while Aurora investors would receive Curaleaf shares.
Peers Moving on This News
FAQs
Q: Why is Aurora Cannabis asking shareholders to reject Curaleaf’s bid?
A: Aurora Cannabis says the hostile bid undervalues its business and fails to provide a meaningful change-of-control premium. It also says shareholders would surrender part of their cash value.
Q: How much cash does Aurora Cannabis have?
A: Aurora Cannabis reported approximately $149 million in cash as of June 30, 2026. The company says that cash belongs to its shareholders and would not be fully received under Curaleaf’s proposal.
Q: What risks does the Curaleaf bid create for ACB investors?
A: Aurora says ACB investors would receive Curaleaf shares and gain exposure to the bidder’s debt, tax uncertainties, regulatory risks, limited liquidity and share-price volatility.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.